ID   ACSL4_HUMAN             Reviewed;         711 AA.
AC   O60488; D3DUY2; O60848; O60849; Q5JWV8;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   27-APR-2001, sequence version 2.
DT   28-JUN-2023, entry version 217.
DE   RecName: Full=Long-chain-fatty-acid--CoA ligase 4 {ECO:0000305};
DE            EC=6.2.1.3 {ECO:0000269|PubMed:21242590, ECO:0000269|PubMed:22633490, ECO:0000269|PubMed:24269233};
DE   AltName: Full=Arachidonate--CoA ligase {ECO:0000305};
DE            EC=6.2.1.15 {ECO:0000269|PubMed:21242590};
DE   AltName: Full=Long-chain acyl-CoA synthetase 4;
DE            Short=LACS 4;
GN   Name=ACSL4; Synonyms=ACS4, FACL4, LACS4;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RX   PubMed=9598324; DOI=10.1006/geno.1998.5268;
RA   Cao Y., Traer E., Zimmerman G.A., McIntyre T.M., Prescott S.M.;
RT   "Cloning, expression, and chromosomal localization of human long-chain
RT   fatty acid-CoA ligase 4 (FACL4).";
RL   Genomics 49:327-330(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LONG AND SHORT), AND INVOLVEMENT IN
RP   ATS-MR.
RC   TISSUE=Placenta, and Retina;
RX   PubMed=9480748; DOI=10.1006/geno.1997.5104;
RA   Piccini M., Vitelli F., Bruttini M., Pober B.R., Jonsson J.J.,
RA   Villanova M., Zollo M., Borsani G., Ballabio A., Renieri A.;
RT   "FACL4, a new gene encoding long-chain acyl-CoA synthetase 4, is deleted in
RT   a family with Alport syndrome, elliptocytosis, and mental retardation.";
RL   Genomics 47:350-358(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT).
RC   TISSUE=Stomach;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM SHORT).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [7]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [8]
RP   CATALYTIC ACTIVITY, FUNCTION, AND ACTIVITY REGULATION.
RX   PubMed=21242590; DOI=10.1194/jlr.m013292;
RA   Golej D.L., Askari B., Kramer F., Barnhart S., Vivekanandan-Giri A.,
RA   Pennathur S., Bornfeldt K.E.;
RT   "Long-chain acyl-CoA synthetase 4 modulates prostaglandin E(2) release from
RT   human arterial smooth muscle cells.";
RL   J. Lipid Res. 52:782-793(2011).
RN   [9]
RP   FUNCTION, AND CATALYTIC ACTIVITY.
RX   PubMed=22633490; DOI=10.1016/j.molcel.2012.04.033;
RA   Nakahara K., Ohkuni A., Kitamura T., Abe K., Naganuma T., Ohno Y.,
RA   Zoeller R.A., Kihara A.;
RT   "The Sjogren-Larsson syndrome gene encodes a hexadecenal dehydrogenase of
RT   the sphingosine 1-phosphate degradation pathway.";
RL   Mol. Cell 46:461-471(2012).
RN   [10]
RP   CATALYTIC ACTIVITY, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=24269233; DOI=10.1016/j.bbrc.2013.11.036;
RA   Ohkuni A., Ohno Y., Kihara A.;
RT   "Identification of acyl-CoA synthetases involved in the mammalian
RT   sphingosine 1-phosphate metabolic pathway.";
RL   Biochem. Biophys. Res. Commun. 442:195-201(2013).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-447, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [12]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [13]
RP   VARIANT XLID63 SER-570.
RX   PubMed=11889465; DOI=10.1038/ng857;
RA   Meloni I., Muscettola M., Raynaud M., Longo I., Bruttini M., Moizard M.-P.,
RA   Gomot M., Chelly J., des Portes V., Fryns J.-P., Ropers H.-H., Magi B.,
RA   Bellan C., Volpi N., Yntema H.G., Lewis S.E., Schaffer J.E., Renieri A.;
RT   "FACL4, encoding fatty acid-CoA ligase 4, is mutated in nonspecific X-
RT   linked mental retardation.";
RL   Nat. Genet. 30:436-440(2002).
RN   [14]
RP   VARIANT [LARGE SCALE ANALYSIS] CYS-133.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S., Buckhaults P.,
RA   Farrell C., Meeh P., Markowitz S.D., Willis J., Dawson D., Willson J.K.V.,
RA   Gazdar A.F., Hartigan J., Wu L., Liu C., Parmigiani G., Park B.H.,
RA   Bachman K.E., Papadopoulos N., Vogelstein B., Kinzler K.W.,
RA   Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal cancers.";
RL   Science 314:268-274(2006).
RN   [15]
RP   VARIANT ASN-379.
RX   PubMed=29961568; DOI=10.1016/j.ajhg.2018.06.001;
RG   NIHR BioResource;
RG   Care4Rare Canada Consortium;
RA   Ito Y., Carss K.J., Duarte S.T., Hartley T., Keren B., Kurian M.A.,
RA   Marey I., Charles P., Mendonca C., Nava C., Pfundt R., Sanchis-Juan A.,
RA   van Bokhoven H., van Essen A., van Ravenswaaij-Arts C., Boycott K.M.,
RA   Kernohan K.D., Dyack S., Raymond F.L.;
RT   "De Novo Truncating Mutations in WASF1 Cause Intellectual Disability with
RT   Seizures.";
RL   Am. J. Hum. Genet. 103:144-153(2018).
CC   -!- FUNCTION: Catalyzes the conversion of long-chain fatty acids to their
CC       active form acyl-CoA for both synthesis of cellular lipids, and
CC       degradation via beta-oxidation (PubMed:24269233, PubMed:22633490,
CC       PubMed:21242590). Preferentially activates arachidonate and
CC       eicosapentaenoate as substrates (PubMed:21242590). Preferentially
CC       activates 8,9-EET > 14,15-EET > 5,6-EET > 11,12-EET. Modulates glucose-
CC       stimulated insulin secretion by regulating the levels of unesterified
CC       EETs (By similarity). Modulates prostaglandin E2 secretion
CC       (PubMed:21242590). {ECO:0000250|UniProtKB:O35547,
CC       ECO:0000269|PubMed:21242590, ECO:0000269|PubMed:22633490,
CC       ECO:0000269|PubMed:24269233}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a long-chain fatty acid + ATP + CoA = a long-chain fatty acyl-
CC         CoA + AMP + diphosphate; Xref=Rhea:RHEA:15421, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:57560,
CC         ChEBI:CHEBI:83139, ChEBI:CHEBI:456215; EC=6.2.1.3;
CC         Evidence={ECO:0000269|PubMed:21242590, ECO:0000269|PubMed:22633490,
CC         ECO:0000269|PubMed:24269233};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:15422;
CC         Evidence={ECO:0000269|PubMed:21242590, ECO:0000269|PubMed:22633490,
CC         ECO:0000269|PubMed:24269233};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(5Z,8Z,11Z,14Z)-eicosatetraenoate + ATP + CoA =
CC         (5Z,8Z,11Z,14Z)-eicosatetraenoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:19713, ChEBI:CHEBI:30616, ChEBI:CHEBI:32395,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:57368,
CC         ChEBI:CHEBI:456215; EC=6.2.1.15;
CC         Evidence={ECO:0000269|PubMed:21242590};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:19714;
CC         Evidence={ECO:0000269|PubMed:21242590};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + CoA + hexadecanoate = AMP + diphosphate + hexadecanoyl-
CC         CoA; Xref=Rhea:RHEA:30751, ChEBI:CHEBI:7896, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:57379,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000269|PubMed:21242590,
CC         ECO:0000269|PubMed:24269233};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:30752;
CC         Evidence={ECO:0000269|PubMed:21242590};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=(E)-hexadec-2-enoate + ATP + CoA = (2E)-hexadecenoyl-CoA + AMP
CC         + diphosphate; Xref=Rhea:RHEA:36139, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:33019, ChEBI:CHEBI:57287, ChEBI:CHEBI:61526,
CC         ChEBI:CHEBI:72745, ChEBI:CHEBI:456215;
CC         Evidence={ECO:0000269|PubMed:22633490, ECO:0000269|PubMed:24269233};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:36140;
CC         Evidence={ECO:0000269|PubMed:22633490};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=15-hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoate + ATP + CoA = 15-
CC         hydroxy-(5Z,8Z,11Z,13E)-eicosatetraenoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:52116, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:78832, ChEBI:CHEBI:136409,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:O35547};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52117;
CC         Evidence={ECO:0000250|UniProtKB:O35547};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=12-hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoate + ATP + CoA = 12-
CC         hydroxy-(5Z,8Z,10E,14Z)-eicosatetraenoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:52112, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:90718, ChEBI:CHEBI:136408,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:O35547};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52113;
CC         Evidence={ECO:0000250|UniProtKB:O35547};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5-hydroxy-(6E,8Z,11Z,14Z)-eicosatetraenoate + ATP + CoA = 5-
CC         hydroxy-(6E,8Z,11Z,14Z)-eicosatetraenoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:52108, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:65341, ChEBI:CHEBI:136407,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:O35547};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52109;
CC         Evidence={ECO:0000250|UniProtKB:O35547};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=5,6-epoxy-(8Z,11Z,14Z)-eicosatrienoate + ATP + CoA = 5,6-
CC         epoxy-(8Z,11Z,14Z)-eicosatrienoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:52088, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:131992, ChEBI:CHEBI:136351,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:O35547};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52089;
CC         Evidence={ECO:0000250|UniProtKB:O35547};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=14,15-epoxy-(5Z,8Z,11Z)-eicosatrienoate + ATP + CoA = 14,15-
CC         epoxy-(5Z,8Z,11Z)-eicosatrienoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:52016, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:84024, ChEBI:CHEBI:136117,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:O35547};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52017;
CC         Evidence={ECO:0000250|UniProtKB:O35547};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=11,12-epoxy-(5Z,8Z,14Z)-eicosatrienoate + ATP + CoA = 11,12-
CC         epoxy-(5Z,8Z,14Z)-eicosatrienoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:52012, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:76625, ChEBI:CHEBI:136115,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:O35547};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52013;
CC         Evidence={ECO:0000250|UniProtKB:O35547};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=8,9-epoxy-(5Z,11Z,14Z)-eicosatrienoate + ATP + CoA = 8,9-
CC         epoxy-(5Z,11Z,14Z)-eicosatrienoyl-CoA + AMP + diphosphate;
CC         Xref=Rhea:RHEA:52008, ChEBI:CHEBI:30616, ChEBI:CHEBI:33019,
CC         ChEBI:CHEBI:57287, ChEBI:CHEBI:84025, ChEBI:CHEBI:136107,
CC         ChEBI:CHEBI:456215; Evidence={ECO:0000250|UniProtKB:O35547};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:52009;
CC         Evidence={ECO:0000250|UniProtKB:O35547};
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Both triacsin C and rosiglitazone inhibit
CC       arachidonoyl-CoA ligase activity. {ECO:0000269|PubMed:21242590}.
CC   -!- SUBCELLULAR LOCATION: Mitochondrion outer membrane {ECO:0000250};
CC       Single-pass type III membrane protein {ECO:0000250}. Peroxisome
CC       membrane {ECO:0000250}; Single-pass type III membrane protein
CC       {ECO:0000250}. Microsome membrane {ECO:0000250}; Single-pass type III
CC       membrane protein {ECO:0000250}. Endoplasmic reticulum membrane
CC       {ECO:0000269|PubMed:24269233}; Single-pass type III membrane protein
CC       {ECO:0000250}. Cell membrane {ECO:0000269|PubMed:24269233}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=O60488-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=O60488-2; Sequence=VSP_000238;
CC   -!- DISEASE: Intellectual developmental disorder, X-linked 63 (XLID63)
CC       [MIM:300387]: A disorder characterized by significantly below average
CC       general intellectual functioning associated with impairments in
CC       adaptive behavior and manifested during the developmental period.
CC       Intellectual deficiency is the only primary symptom of non-syndromic X-
CC       linked intellectual disability, while syndromic forms presents with
CC       associated physical, neurological and/or psychiatric manifestations.
CC       {ECO:0000269|PubMed:11889465}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: AMME complex (ATS-MR) [MIM:300194]: An X-linked contiguous
CC       gene deletion syndrome characterized by glomerulonephritis,
CC       sensorineural hearing loss, intellectual disability, midface hypoplasia
CC       and elliptocytosis. {ECO:0000269|PubMed:9480748}. Note=The gene
CC       represented in this entry may be involved in disease pathogenesis.
CC   -!- SIMILARITY: Belongs to the ATP-dependent AMP-binding enzyme family.
CC       {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF030555; AAC17493.1; -; mRNA.
DR   EMBL; Y12777; CAA73314.1; -; mRNA.
DR   EMBL; Y13058; CAA73501.1; -; mRNA.
DR   EMBL; AK292070; BAF84759.1; -; mRNA.
DR   EMBL; CH471120; EAX02671.1; -; Genomic_DNA.
DR   EMBL; CH471120; EAX02672.1; -; Genomic_DNA.
DR   EMBL; CH471120; EAX02673.1; -; Genomic_DNA.
DR   EMBL; CH471120; EAX02674.1; -; Genomic_DNA.
DR   EMBL; BC034959; AAH34959.1; -; mRNA.
DR   CCDS; CCDS14548.1; -. [O60488-1]
DR   CCDS; CCDS14549.1; -. [O60488-2]
DR   RefSeq; NP_001305438.1; NM_001318509.1. [O60488-1]
DR   RefSeq; NP_001305439.1; NM_001318510.1. [O60488-2]
DR   RefSeq; NP_004449.1; NM_004458.2. [O60488-2]
DR   RefSeq; NP_075266.1; NM_022977.2. [O60488-1]
DR   RefSeq; XP_005262166.1; XM_005262109.2. [O60488-1]
DR   RefSeq; XP_006724698.1; XM_006724635.2. [O60488-2]
DR   RefSeq; XP_011529190.1; XM_011530888.2. [O60488-1]
DR   RefSeq; XP_011529191.1; XM_011530889.2. [O60488-1]
DR   AlphaFoldDB; O60488; -.
DR   SMR; O60488; -.
DR   BioGRID; 108478; 157.
DR   IntAct; O60488; 56.
DR   MINT; O60488; -.
DR   STRING; 9606.ENSP00000339787; -.
DR   BindingDB; O60488; -.
DR   ChEMBL; CHEMBL4680022; -.
DR   DrugBank; DB00159; Icosapent.
DR   DrugBank; DB00412; Rosiglitazone.
DR   DrugBank; DB00197; Troglitazone.
DR   SwissLipids; SLP:000000201; -.
DR   SwissLipids; SLP:000000515; -. [O60488-1]
DR   SwissLipids; SLP:000000516; -. [O60488-2]
DR   GlyGen; O60488; 3 sites, 1 O-linked glycan (3 sites).
DR   iPTMnet; O60488; -.
DR   MetOSite; O60488; -.
DR   PhosphoSitePlus; O60488; -.
DR   SwissPalm; O60488; -.
DR   BioMuta; ACSL4; -.
DR   EPD; O60488; -.
DR   jPOST; O60488; -.
DR   MassIVE; O60488; -.
DR   MaxQB; O60488; -.
DR   PaxDb; O60488; -.
DR   PeptideAtlas; O60488; -.
DR   ProteomicsDB; 49426; -. [O60488-1]
DR   ProteomicsDB; 49427; -. [O60488-2]
DR   Antibodypedia; 444; 396 antibodies from 37 providers.
DR   DNASU; 2182; -.
DR   Ensembl; ENST00000340800.7; ENSP00000339787.2; ENSG00000068366.21. [O60488-1]
DR   Ensembl; ENST00000348502.10; ENSP00000262835.7; ENSG00000068366.21. [O60488-2]
DR   Ensembl; ENST00000469796.7; ENSP00000419171.2; ENSG00000068366.21. [O60488-1]
DR   Ensembl; ENST00000502391.6; ENSP00000425408.2; ENSG00000068366.21. [O60488-1]
DR   Ensembl; ENST00000671846.1; ENSP00000500897.1; ENSG00000068366.21. [O60488-1]
DR   Ensembl; ENST00000672282.1; ENSP00000500678.1; ENSG00000068366.21. [O60488-2]
DR   Ensembl; ENST00000672401.1; ENSP00000500273.1; ENSG00000068366.21. [O60488-2]
DR   Ensembl; ENST00000673016.1; ENSP00000499969.1; ENSG00000068366.21. [O60488-2]
DR   GeneID; 2182; -.
DR   KEGG; hsa:2182; -.
DR   MANE-Select; ENST00000672401.1; ENSP00000500273.1; NM_001318510.2; NP_001305439.1. [O60488-2]
DR   UCSC; uc004eoi.3; human. [O60488-1]
DR   AGR; HGNC:3571; -.
DR   CTD; 2182; -.
DR   DisGeNET; 2182; -.
DR   GeneCards; ACSL4; -.
DR   HGNC; HGNC:3571; ACSL4.
DR   HPA; ENSG00000068366; Low tissue specificity.
DR   MalaCards; ACSL4; -.
DR   MIM; 300157; gene.
DR   MIM; 300194; phenotype.
DR   MIM; 300387; phenotype.
DR   neXtProt; NX_O60488; -.
DR   OpenTargets; ENSG00000068366; -.
DR   Orphanet; 86818; Alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndrome.
DR   Orphanet; 777; X-linked non-syndromic intellectual disability.
DR   PharmGKB; PA27968; -.
DR   VEuPathDB; HostDB:ENSG00000068366; -.
DR   eggNOG; KOG1180; Eukaryota.
DR   GeneTree; ENSGT00940000157427; -.
DR   HOGENOM; CLU_000022_45_2_1; -.
DR   InParanoid; O60488; -.
DR   OrthoDB; 443463at2759; -.
DR   PhylomeDB; O60488; -.
DR   TreeFam; TF314012; -.
DR   BioCyc; MetaCyc:HS00935-MON; -.
DR   BRENDA; 6.2.1.15; 2681.
DR   BRENDA; 6.2.1.3; 2681.
DR   PathwayCommons; O60488; -.
DR   Reactome; R-HSA-434313; Intracellular metabolism of fatty acids regulates insulin secretion.
DR   Reactome; R-HSA-75876; Synthesis of very long-chain fatty acyl-CoAs.
DR   SignaLink; O60488; -.
DR   BioGRID-ORCS; 2182; 88 hits in 803 CRISPR screens.
DR   ChiTaRS; ACSL4; human.
DR   GeneWiki; ACSL4; -.
DR   GenomeRNAi; 2182; -.
DR   Pharos; O60488; Tbio.
DR   PRO; PR:O60488; -.
DR   Proteomes; UP000005640; Chromosome X.
DR   RNAct; O60488; protein.
DR   Bgee; ENSG00000068366; Expressed in adrenal tissue and 192 other tissues.
DR   ExpressionAtlas; O60488; baseline and differential.
DR   Genevisible; O60488; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:UniProtKB.
DR   GO; GO:0005789; C:endoplasmic reticulum membrane; TAS:Reactome.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0005811; C:lipid droplet; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0044233; C:mitochondria-associated endoplasmic reticulum membrane; IDA:MGI.
DR   GO; GO:0005741; C:mitochondrial outer membrane; TAS:Reactome.
DR   GO; GO:0005778; C:peroxisomal membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0047676; F:arachidonate-CoA ligase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004467; F:long-chain fatty acid-CoA ligase activity; IDA:UniProtKB.
DR   GO; GO:0090433; F:palmitoyl-CoA ligase activity; TAS:Reactome.
DR   GO; GO:0031957; F:very long-chain fatty acid-CoA ligase activity; IMP:UniProtKB.
DR   GO; GO:0060136; P:embryonic process involved in female pregnancy; IEA:Ensembl.
DR   GO; GO:0006631; P:fatty acid metabolic process; TAS:Reactome.
DR   GO; GO:0008610; P:lipid biosynthetic process; IDA:UniProtKB.
DR   GO; GO:0006629; P:lipid metabolic process; IDA:UniProtKB.
DR   GO; GO:0001676; P:long-chain fatty acid metabolic process; IDA:UniProtKB.
DR   GO; GO:0035338; P:long-chain fatty-acyl-CoA biosynthetic process; TAS:Reactome.
DR   GO; GO:0035336; P:long-chain fatty-acyl-CoA metabolic process; IBA:GO_Central.
DR   GO; GO:0032307; P:negative regulation of prostaglandin secretion; IDA:UniProtKB.
DR   GO; GO:0030182; P:neuron differentiation; IBA:GO_Central.
DR   GO; GO:0030307; P:positive regulation of cell growth; IDA:UniProtKB.
DR   GO; GO:0032024; P:positive regulation of insulin secretion; ISS:UniProtKB.
DR   CDD; cd17639; LC_FACS_euk1; 1.
DR   Gene3D; 3.30.300.30; -; 1.
DR   Gene3D; 3.40.50.12780; N-terminal domain of ligase-like; 1.
DR   InterPro; IPR045851; AMP-bd_C_sf.
DR   InterPro; IPR020845; AMP-binding_CS.
DR   InterPro; IPR000873; AMP-dep_Synth/Lig_com.
DR   InterPro; IPR042099; ANL_N_sf.
DR   PANTHER; PTHR43272; LONG-CHAIN-FATTY-ACID--COA LIGASE; 1.
DR   PANTHER; PTHR43272:SF22; LONG-CHAIN-FATTY-ACID--COA LIGASE 4; 1.
DR   Pfam; PF00501; AMP-binding; 1.
DR   SUPFAM; SSF56801; Acetyl-CoA synthetase-like; 1.
DR   PROSITE; PS00455; AMP_BINDING; 1.
PE   1: Evidence at protein level;
KW   Alport syndrome; Alternative splicing; ATP-binding; Cell membrane;
KW   Deafness; Disease variant; Elliptocytosis; Endoplasmic reticulum;
KW   Fatty acid metabolism; Hereditary hemolytic anemia;
KW   Intellectual disability; Ligase; Lipid metabolism; Magnesium; Membrane;
KW   Microsome; Mitochondrion; Mitochondrion outer membrane; Nucleotide-binding;
KW   Peroxisome; Phosphoprotein; Reference proteome; Signal-anchor;
KW   Transmembrane; Transmembrane helix.
FT   CHAIN           1..711
FT                   /note="Long-chain-fatty-acid--CoA ligase 4"
FT                   /id="PRO_0000193109"
FT   TRANSMEM        8..28
FT                   /note="Helical; Signal-anchor for type III membrane
FT                   protein"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        29..711
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   MOD_RES         447
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..41
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:9480748,
FT                   ECO:0000303|PubMed:9598324"
FT                   /id="VSP_000238"
FT   VARIANT         133
FT                   /note="R -> C (in a colorectal cancer sample; somatic
FT                   mutation; dbSNP:rs753267653)"
FT                   /evidence="ECO:0000269|PubMed:16959974"
FT                   /id="VAR_036376"
FT   VARIANT         379
FT                   /note="D -> N"
FT                   /evidence="ECO:0000269|PubMed:29961568"
FT                   /id="VAR_083476"
FT   VARIANT         570
FT                   /note="R -> S (in XLID63; dbSNP:rs122458138)"
FT                   /evidence="ECO:0000269|PubMed:11889465"
FT                   /id="VAR_013180"
FT   CONFLICT        181
FT                   /note="Y -> C (in Ref. 2; CAA73314)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   711 AA;  79188 MW;  6483CD17FE78FE73 CRC64;
     MKLKLNVLTI ILLPVHLLIT IYSALIFIPW YFLTNAKKKN AMAKRIKAKP TSDKPGSPYR
     SVTHFDSLAV IDIPGADTLD KLFDHAVSKF GKKDSLGTRE ILSEENEMQP NGKVFKKLIL
     GNYKWMNYLE VNRRVNNFGS GLTALGLKPK NTIAIFCETR AEWMIAAQTC FKYNFPLVTL
     YATLGKEAVV HGLNESEASY LITSVELLES KLKTALLDIS CVKHIIYVDN KAINKAEYPE
     GFEIHSMQSV EELGSNPENL GIPPSRPTPS DMAIVMYTSG STGRPKGVMM HHSNLIAGMT
     GQCERIPGLG PKDTYIGYLP LAHVLELTAE ISCFTYGCRI GYSSPLTLSD QSSKIKKGSK
     GDCTVLKPTL MAAVPEIMDR IYKNVMSKVQ EMNYIQKTLF KIGYDYKLEQ IKKGYDAPLC
     NLLLFKKVKA LLGGNVRMML SGGAPLSPQT HRFMNVCFCC PIGQGYGLTE SCGAGTVTEV
     TDYTTGRVGA PLICCEIKLK DWQEGGYTIN DKPNPRGEIV IGGQNISMGY FKNEEKTAED
     YSVDENGQRW FCTGDIGEFH PDGCLQIIDR KKDLVKLQAG EYVSLGKVEA ALKNCPLIDN
     ICAFAKSDQS YVISFVVPNQ KRLTLLAQQK GVEGTWVDIC NNPAMEAEIL KEIREAANAM
     KLERFEIPIK VRLSPEPWTP ETGLVTDAFK LKRKELRNHY LKDIERMYGG K
//
